HSPA5 and breast carcinoma: Intriguingly it has been shown that while high GRP78 levels are predictive of a shorter time to recurrence in stage II and III breast cancer patients treated with the topoisomerase inhibitor doxorubicin (Lee et al., 2006; Scriven et al., 2009), in patients treated sequentially with doxorubicin and taxanes GRP78 is positively associated with better outcome (Lee et al., 2011).